NICE confirms support for Amgen's Nplate
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has published final draft guidance recommending Amgen's thrombopoietin receptor agonist Nplate (romiplostim) for some patients with chronic idiopathic thrombocytopenic purpura (ITP).